GRN and frontotemporal dementia: Worthy of mention is the ongoing trial INFRONT-3, a phase three double-blind, placebo-controlled study evaluating the AL001 efficacy and safety in participants at risk for or with FTD due to heterozygous mutations in the progranulin gene (NCT04374136).